A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus
Background and Objectives: Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers.Unfortunately, at their time of diagnosis, most patients have advanced to unresectable disease with a very MULTI-ZYME poor prognosis.The oriental herbal medicine HangAm-Plus (HAP) has been developed for antitumor purposes, and several prev